Protein linked with neurodegenerative diseases may help explore the aggressive behavior of gliomas

A protein typically associated with neurodegenerative diseases like Alzheimer's might help scientists explore how gliomas, a type of cancerous brain tumor, become so aggressive.

The new study, in mouse models and human brain tumor tissues, was published in Science Translational Medicine and found a significant expression of the protein TAU in glioma cells, especially in those patients with better prognoses.

Patients with glioma are given a better prognosis when their tumor expresses a mutation in a gene called isocitrate dehydrogenase 1 (IDH1).

In this international collaborative study led by the Instituto de Salud Carlos III-UFIEC in Madrid, Spain, those IDHI mutations stimulated the expression of TAU. Then, the presence of TAU acted as a brake for the formation of new blood vessels, which are necessary for the aggressive behavior of the tumors.

We report that the levels of microtubule-associated protein TAU, which have been associated with neurodegenerative diseases, are epigenetically controlled by the balance between normal and mutant IDH1/2 in mouse and human gliomas. In IDH1/2 mutant tumors, we found that expression levels of TAU decreased with tumor progression."

Maria G. Castro, Ph.D.co-author and professor of neurosurgery and cell and developmental biology, Michigan Medicine

That means levels of TAU could be used as a biomarker for tumor progression in mutant IDH1/2 gliomas, Castro says.

Source:
Journal reference:

Gargini, R. et al. (2020) The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas. Science Translational Medicine .doi.org/10.1126/scitranslmed.aax1501.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study identifies potential treatment for tauopathies using carbonic anhydrase inhibitors